Search Videos and More
News
Dana-Farber Leads Adaptive, Efficient Multi-arm Phase 2 Clinical Trial for Glioblastoma
An innovative phase 2 clinical trial led by Dana-Farber Cancer Institute in collaboration with 10 major brain tumor centers around the country and designed to find new potential treatments for glioblastoma has reported initial results in the Journal of Clinical Oncology.
News
Dana-Farber Research Publication 09.15.2023
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
News
Dana-Farber Research Publication 9.15.2022
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
News
Dana-Farber Study Finds Up-front Chemotherapy Boost Could Benefit Patients with Non-Small Cell Lung Cancer
In a phase 3 global clinical trial called FLAURA2 led by researchers from Dana-Farber Cancer Institute and Institut Gustav Roussy in France, patients with non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation taking standard therapy plus chemotherapy had a median of nearly 9 months increase in progression free survival compared with patients taking standard therapy alone.
News
Dana-Farber Research Publication 9.1.2022
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
News
Potent Oral Agent Acting as Immunotherapy and Targeted Treatment Produces High Response Rate in Certain Patients
A new agent that subverts myeloma cells from within while also subjecting them to an immune system attack produced impressive responses in combination with dexamethasone in patients with multiple myeloma that had relapsed and stopped responding to all currently available therapies, a clinical trial conducted by researchers at Dana-Farber Cancer Institute and around the world has found.
News
Final Overall Study Analysis Continues to Show Benefit of Sacituzumab Govitecan in Advanced HR+ Breast Cancer
A novel antibody-drug conjugate continues to demonstrate superior benefit for patients with HR+, HER2- metastatic breast cancer when compared to standard chemotherapy, according to a new study in The Lancet.
News
Allogenic Hematopoietic Cell Transplant a Viable Option for all Patients with High-Risk MDS
Allogeneic Hematopoietic Cell Transplantation Improves Outcome in MDS across High-Risk genetic subgroups: Genetic analysis of the BMT CTN 1102 study
News
Cell Therapy That Repairs Cornea Damage with Patient’s Own Stem Cells Achieves Positive Phase I Trial Results
A team led by researchers from Dana-Farber Cancer Institute and Mass Eye and Ear, a member of Mass General Brigham, reports the results of a phase I trial of a revolutionary stem cell treatment called cultivated autologous limbal epithelial cell transplantation (CALEC), which was found to be safe and well-tolerated over the short term in four patients with significant chemical burns in one eye.
News
Study Shows Immunotherapy May Benefit a Subset of Patients with Penile Cancer
Penile cancer is a rare disease with approximately 2070 new cases each year in the US.
News
Study Uncovers Epigenetic Source of Resistance to Targeted Therapy in EGFR-mutant Lung Cancer
When lung cancers driven by mutations in the EGFR gene become resistant to osimertinib or other targeted therapies, epigenetic changes, rather than genetic changes, are often to blame.
News
AI-Driven Muscle Mass Assessment Could Improve Care for Head and Neck Cancer Patients
Researchers from Dana-Farber Cancer Institute have found a way to use artificial intelligence (AI) to diagnose muscle wasting, called sarcopenia, in patients with head and neck cancer.